Hemangiomas and Other Congenital Malformations in Infants Exposed to Antiretroviral Therapy In Utero
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Pregnancy is not an indication for discontinuing or delaying combined antiretroviral therapy (CART) in women with human immunodeficiency virus (HIV) infection, but concerns remain about potential adverse effects for the infant.1-2 Prior small case series have suggested an increased risk for hemangioma.3-4 We assessed the risk of hemangioma and other congenital malformations in a somewhat larger cohort of infants exposed to CART in utero, as well as in a comparison cohort.
Methods
We assessed the outcomes of all pregnancies in HIV-positive women (69 cases with 2 twins) receiving CART who delivered between 1997 and 2002 at the Catholic University of the Sacred Heart, Rome. Data were compared with a control group of 284 cases selected among HIV-negative women who contacted our Teratology Information Service for counseling about drugs that are not known or suspected to be teratogenic. We assessed infants for the presence of any congenital anomalies, including . . . [Full Text of this Article]
Marco De Santis, MD;
Anna Franca Cavaliere, MD;
Alessandro Caruso, MD
Telefono Rosso—Teratology Information Service
Department of Obstetrics and Gynaecology
Paola Villa, MD
Department of Obstetrics and Gynaecology
Enrica Tamburrini, MD;
Roberto Cauda, MD
Department of Infectious Disease
Carlo Fundaro, MD;
Orazio Genovese, MD
Department of Pediatrics
Catholic University of the Sacred Heart
Rome, Italy
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Combined Antiretroviral Therapy During Pregnancy and Risk of Congenital Malformations
Frieden et al.
JAMA 2004;291:1961-1962.
FULL TEXT
|
